Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $71.00. The company’s shares closed last Monday at $22.23, close to its 52-week low of $18.27.
According to TipRanks.com, Yang has 0 stars on 0-5 star ranking scale with an average return of -4.9% and a 35.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Revance Therapeutics, and Nektar Therapeutics.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $55.80, which is a 160.7% upside from current levels. In a report issued on February 14, Stifel Nicolaus also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Zogenix’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $290 million. In comparison, last year the company had a GAAP net loss of $22.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
Read More on ZGNX:
